Dr. Tomer was born and raised in Tel Aviv. He received his bachelor’s degree in Pharmacy in from the School of Pharmacy at the Hebrew University of Jerusalem and pursued his PhD research at the School of Pharmacy at the University of London, which he completed in 1994. Dr. Ron Tomer also holds an MBA from the Recanati School of Business at the Tel Aviv University.
Ron joined Unipharm in 1995. Since then, Ron has contributed to Unipharm’s significant growth, transforming it into one of Israel’s largest generic pharmaceutical companies and a drug supplier to hundreds of thousands of Israeli citizens.
Dr. Ron Tomer served for many years as a Board Member and Head of the Professional Committee of the Pharmacy Society of Israel (PSI).
He headed various activities of the Manufacturers’ Association of Israel (MAI). In early 2020, he was elected as the President of the Manufacturers’ Association of Israel, representing all sectors of the Israeli Industries and the High-Tech sector, working with the Israeli Government to support the industrial growth and production independence of Israel. Under his leadership, the industrial production in Israel has reached an unprecedented level.
Dr. Tomer is an expert in the fields of formulation development and pharmaceutical patents and actively pursues patent challenges that introduce generic drug competition into the market.
Having been born and raised in Tel Aviv, Gil received his bachelor’s degree in Pharmacy in from the School of Pharmacy at the Hebrew University of Jerusalem and pursued his PhD research at the School of Pharmacy at the University of London in the field of industrial pharmaceutics, which he completed in 1999 after publishing six research papers. He also holds an MBA from the Kellogg School of Management, Northwestern University, and the Leon Recanati Graduate School of Business, Tel Aviv University.
Gil joined the family business in 1999. Since then, he has contributed to Unipharm’s significant growth, transforming it into one of Israel’s largest generic pharmaceutical companies. Gil was responsible for the design and construction of Unipharm’s Mevo Carmel manufacturing facility. Since 2017, he is the Head of this state-of-the-art facility, overseeing Unipharm’s Quality Assurance, Quality Control, Regulatory Affairs, Operations, Purchasing, Finance, and Information Technologies Departments.
Gil was the lecturer and coordinator of a graduate course in Industrial Pharmacy at the School of Pharmacy at the Hebrew University of Jerusalem during 2012-2019.
He has been an active volunteer at the Pharmaceutical Society of Israel for over 15 years, took part in the initiation of the Pharmaceutical Society’s Pharmacovigilance Forum, and founded and has been leading the program for regulatory affairs for many years.
Zevulun Tomer was born and raised in Tel Aviv. He received his M. Pharm degree in 1960 from the School of Pharmacy at the Hebrew University of Jerusalem. From that moment on, he was actively engaged in the Israeli Pharmaceutical Industry, playing a key role in its growth. Zevulun began his career in 1960 as the Qualified Pharmacist of Plantex, an API company owned by Baron Edmond James de Rothschild, founded in Israel in 1959. Over the years he held the roles of Head of Production, Head of R&D, and Head of Operations and Commercial, helping Plantex become an industry leader. In 1968 he founded Pharma-Plantex, an affiliate company focusing on the development of pharmaceutical products. In 1969 he was appointed CEO of Plantex and transferred much of the company’s R&D and production from plant-based extracts to unique chemical syntheses.
In 1975, Zevulun founded Unipharm, with the close support of his late wife Shoshana. By seeking new APIs, Zevulun enabled numerous launches of new generic drug products in Israel as the first generic market, expediting the entrance of generic competition worldwide. Zevulun Tomer was an entrepreneur by nature, displaying a mastery of research and a deep understanding of patent law, and was considered a leader in the field. He initiated patent litigations against multinational pharmaceutical companies, the vast majority of which were won.